USPTO serial 79274041
AKRIVICELL
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Aug 11, 2020
- Examiner
- WILSON, MARYNELLE WEST
- Law office
- PUBLICATION AND ISSUE SECTION
What this means
This registration is in, or will soon enter, a USPTO maintenance window. Missing a Section 8 or Section 9 filing can cancel the registration.
Need help with AKRIVICELL?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Get help with this Renewal, set up monitoring, or talk with CopyMark.
Get Attorney Assistance for just $797*
Plus Government fees of $1,275
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
DAVID M. TENER
DAVID M. TENER Caesar Rivise, PC500 Office Center DriveSuite 400Fort Washington, PA 19034Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 009 | Biochips for research or scientific purposes; bioreactor for cell culturing; bioreactors for laboratory use; bioreactors for medical research use; cell culture apparatus for laboratory use, namely, cell culture dishes; laboratory devices for analyzing genome information; devices for analyzing protein sequence used as laboratory apparatus; DNA chips; DNA microarray; non-medical imaging devices for scientific purposes; non-medical immunostaining instruments for scientific purposes; non-medical incubation plates for scientific or laboratory use; incubators for laboratory use; non-medical diagnostic instruments for DNA analysis for scientific research use, not for medical use; laboratory apparatus and instruments for extracting DNA; laboratory incubators other than for medical use; laboratory instruments in the nature of cell sorter, flow cytometer, cell isolator, cell counter and liquid dispensers other than for medical use; laboratory optical apparatus, namely, optical mirrors; LED microscopes; non-medical lasers for scientific use; lenses for microscopes; microarray slides for laboratory use; microplate readers; microscope slides; glass ware models for scientific experiments in laboratories; nucleic acid sequencers for scientific purposes; petri dishes; petri dishes used in laboratory research; pipette tips; pipettes; scientific distillation apparatus and instruments; print heads for inkjet document printers; disposable plastic bioreactors for cell culture; bioreactors for cell culture; laboratory apparatus, namely liquid dispensers for fabrication of three-dimensional tissues and organs; scientific research and laboratory apparatus and instruments in the nature of cell sorters, flow cytometers, cell isolators, cell counters and liquid dispensers in the field of cytology; equipment for scientific research and laboratory apparatus and instruments in the name of cell sorters, flow cytometers, cell isolators, cell counters, liquid dispensers in the field of cytology; scientific research and laboratory apparatus, namely, cell handling apparatus in the nature of petri dishes, cell analysis and cell separation apparatus in the nature of flow cytometers and flow-based analyzers providing cell and particle analysis, detection, or counting; scientific research and laboratory apparatus, namely, cell culture apparatus in the nature of petri dishes for laboratory use; laboratory apparatus and instruments in the nature of biochips for use in biopharmaceutical discovery and development for research or scientific purposes; laboratory apparatus and instruments in the nature of biochips for use in cell detection and molecular discovery for research or scientific purposes; laboratory apparatus and instruments for the analysis, retrieval or discovery of single cells; laboratory apparatus and instruments for use in assuring monoclonality; replacement parts and fittings for all the aforesaid goods; laboratory apparatus, namely liquid dispensers for fabrication of three dimensional (3D) living tissues; laboratory equipment for scientific and research use, namely, systems comprised of fluid dispenser, imaging station, computer hardware, control software, analysis for software, chips and reagents | ACTIVE | — |
| 010 | Tools for medical diagnostics of cancer, autoimmune disease, heart disease, brain disease, respiratory disease; diagnostic apparatus for use in the diagnosis of cancer, autoimmune disease, heart disease, brain disease, liver disease, respiratory disease for medical purposes; diagnostic instruments for use in the diagnosis of cancer, autoimmune disease, heart disease, brain disease, liver disease, respiratory disease for medical use; testing probes for medical diagnostic purposes, diagnostic imaging apparatus for medical use; optical imaging apparatus for medical diagnostic use; membrane test plates for use in medical diagnostics; apparatus for carrying out diagnostic tests of cancer, autoimmune disease, heart disease, brain disease, liver disease, respiratory disease and for prenatal testing for medical purposes; cell culture instruments for medical use, namely, cell culture chambers; inkjet devices making use of medical imaging technologies, namely, inkjet-based medical imaging apparatus for use in medical research and genetic research and in other medical fields where molecular or cell separations are needed; diagnostic testing apparatus in the nature of cell sorters, flow cytometers, cell isolators, cell counters and liquid dispensers for use in immunoassay procedures for medical use; diagnostic testing instruments in the nature of cell sorters, flow cytometers, cell isolators, cell counters and liquid dispensers for use in immunoassay procedures for medical use; medical apparatus and instruments in the fields of cytology, namely, cell sorters, flow cytometers, cell isolators, cell counters, liquid dispensers | ACTIVE | — |
| 042 | Biological research, scientific clinical research and medical research; biomedical research services; scientific clinical research; development of pharmaceutical preparations and medicines; laboratory research services relating to pharmaceuticals; laboratory research services relating to dermatology; laboratory research services relating to the production of monoclonal antibodies; medical laboratory services; medical research; pharmaceutical drug development services; pharmaceutical product evaluation; pharmaceutical products development; pharmaceutical research and development; pharmaceutical research services; scientific research and development for the pharmaceutical industry; research and development in the pharmaceutical and biotechnology fields; research and development of vaccines and medicines; scientific research and development; scientific research for medical purposes in the area of cancerous diseases; scientific research in the field of pharmacy; services in the nature of pharmaceutical production, namely, development of pharmaceutical preparations; evaluation for assessing the efficiency of pharmaceuticals; services in the nature of product quality evaluation for assessing the efficiency of veterinary drugs; testing of pharmaceuticals; research and development services in the field of antibodies; research and development in the field of microorganisms and cells; scientific laboratory services relating to the isolation and cultivation of human tissues and cells; medical research relating to medicine; medical research relating to medicines; design and development of diagnostic apparatus; design of diagnostic apparatus and equipment; design and development of medical diagnostic apparatus; research and development in the field of diagnostic preparations; research and development services in the field of cytology; biotechnology research; biotechnology testing for scientific research purposes; research and development in the field of biotechnology; research relating to biotechnology; consultancy relating to biotechnology; consultancy in the field of biotechnology; scientific and medical research and development in the field of cytology; scientific and medical research and development in the field of bioprinting | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Cellenion SASU
- Other trademarks owned by Cellenion SASU
- Other trademarks owned by Cellenion SASU
- Other trademarks in Class 009
- Other trademarks in Class 010
- Other trademarks in Class 042
- Similar marks named AKRIVICELL
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Mar 23, 2026 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Mar 23, 2026 | ECDR | TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS | — |
| Mar 23, 2026 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Mar 23, 2026 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Aug 11, 2025 | REM3 | COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED | — |
| Aug 19, 2023 | NREP | NEW REPRESENTATIVE AT IB RECEIVED | — |
| Dec 20, 2020 | FINO | FINAL DECISION TRANSACTION PROCESSED BY IB | — |
| Nov 29, 2020 | FICS | FINAL DISPOSITION NOTICE SENT TO IB | — |
| Nov 29, 2020 | FIMP | FINAL DISPOSITION PROCESSED | — |
| Nov 11, 2020 | FICR | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | — |
| Aug 11, 2020 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| May 26, 2020 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| May 26, 2020 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| May 6, 2020 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Apr 17, 2020 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Apr 17, 2020 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Apr 17, 2020 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Apr 17, 2020 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Apr 17, 2020 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Mar 19, 2020 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Mar 19, 2020 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Mar 19, 2020 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Feb 15, 2020 | RFNT | REFUSAL PROCESSED BY IB | — |
| Jan 31, 2020 | DOCK | ASSIGNED TO EXAMINER | — |
| Jan 29, 2020 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Jan 29, 2020 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Jan 3, 2020 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Jan 2, 2020 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Dec 20, 2019 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Dec 16, 2019 | DOCK | ASSIGNED TO EXAMINER | — |
| Dec 16, 2019 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Dec 12, 2019 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |